1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Asia Pacific (India, China, Australia, South Korea & Others) Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long Acting, Type I & II Diabetes, Analogs & Recombinant Insulin) Analysis And Segment Forecasts To 2020

Asia Pacific (India, China, Australia, South Korea & Others) Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long Acting, Type I & II Diabetes, Analogs & Recombinant Insulin) Analysis And Segment Forecasts To 2020

  • May 2016
  • -
  • Grand View Research
  • -
  • 80 pages

Summary

Table of Contents

The Asia Pacific market for Insulin is expected to reach USD 15.04 billion by 2020. Growing regional prevalence of diabetes, increasing market penetration rates of modern insulin products in emerging markets such as India and China is expected to drive market growth during the forecast period. Furthermore, patent expiration of key products such as Lantus is expected to trigger the manufacturing of biosimilars from local manufacturers such as Biocon.

Long acting analog dominated the overall market in terms of revenue share in 2013, with revenue estimated at USD 2,051.9 million. High prices coupled with relatively higher efficacies exhibited by these products account for its large share. Rapid acting analogs followed the long acting segment in 2013 accounting for a revenue share of over 25.0% on account of their high market penetration rates in developed markets such as Australia and Japan.

Further Key findings from the study suggest:

The analogs source segment accounted for the largest revenue share in 2013 was valued at USD 3,441.7 million. Growing demand for analogs in emerging markets with high unmet medical needs such as China and India is one of the major factors attributing to its large share.

Japan, on behalf of its sophisticated healthcare infrastructure, high patient awareness and disposable income levels dominated the market in 2013 with a revenue share of over 38.0%.

China on the other hand is expected to register the highest CAGR of 21.1% during the forecast period owing to the growing prevalence of type I and type diabetes and the expected decline in insulin prices as a result of continued initiatives to improve healthcare access.

The Asia Pacific insulin market is oligopolistic in nature and is dominated by three key players including Novo Nordisk, Eli Lilly and Sanofi Aventis.

For the purpose of this study, Grand View Research has segmented the Asia Pacific Insulin market on the basis of product, application, source and region:

- Insulin Product Outlook
- Rapid acting
- Long acting
- Premixed
- Premixed analog
- Short acting
- Intermediate acting
- Insulin Application Outlook
- Type I and Other Diabetes
- Type II Diabetes
- Insulin Source Outlook
- Human Recombinant
- Analogs
- Insulin Regional Outlook
- India
- China
- Australia
- New Zealand
- South Korea
- Taiwan
- Philippines
- Vietnam
- Indonesia
- Japan
- Malaysia
- Thailand
- Rest of Asia Pacific

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

  • $ 6995
  • Industry report
  • March 2017
  • by GBI Research

Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products Summary Fatty liver disease (FLD) comprises a spectrum of chronic ...

Pen Needles Market Analysis By Product (Standard Pen Needles, Safety Pen Needles), By Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), By Therapy (Insulin, Glucagon-like-Peptide-1 [GLP-1], Growth Hormone), And Segment Forecasts, 2014 - 2025

Pen Needles Market Analysis By Product (Standard Pen Needles, Safety Pen Needles), By Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), By Therapy (Insulin, Glucagon-like-Peptide-1 [GLP-1], Growth Hormone), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • March 2017
  • by Grand View Research

The global pen needles market is expected to reach a value of USD 4.8 billion by 2025, according to a new report by Grand View Research, Inc. Rising prevalence of diabetes is the primary reason for the ...

Global Insulin Market - Industry Analysis and forecast (2017 - 2022)

Global Insulin Market - Industry Analysis and forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The global insulin market is expected to reach USD 42 billion by 2020, growing at a CAGR of XX%. Insulin is a peptide hormone secreted by the beta cells in the pancreas. Insulin maintains the metabolism ...

Insulin Markets In China

April 2017 $ 4000

Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • April 2017
    44 pages
  • Therapy  

    Serotonin Speci...  

    Antidepressant  

  • United States  

View report >

Diabetes Statistics

  • April 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Hormone and Therapy Market in Pakistan and the US

  • April 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Biosimilar Industry

23 days ago

Related Market Segments :

Insulin

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.